Insulin glulisine - Biologic Drug Details

Summary for insulin glulisine

Tradenames:	1
High Confidence Patents:	1
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for insulin glulisine

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin glulisine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin glulisine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2018-06-18	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2022-03-22	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2027-03-08	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2028-10-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin glulisine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2035-07-16	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629		2036-09-08	Patent claims search

International Patents for insulin glulisine

Country	Patent Number	Estimated Expiration
Brazil	9803708
Montenegro	00408
Denmark	2263723
Israel	125006

Supplementary Protection Certificates for insulin glulisine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SZ 2/2005	Austria		PRODUCT NAME: INSULIN GLULISINE
CA 2005 00018	Denmark		PRODUCT NAME: INSULIN GLULISIN
300170	Netherlands		PRODUCT NAME: INSULINE-GLULISINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/285/002 20040928
2/2005	Austria		PRODUCT NAME: INSULIN GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001-020 20040927

Market Dynamics and Financial Trajectory for Insulin Glulisine

Last updated: August 2, 2025

Introduction

Insulin glulisine represents a rapid-acting insulin analog developed by Sanofi, approved by the U.S. Food and Drug Administration (FDA) in 2009 for the management of diabetes mellitus. As a biosimilar to traditional insulins, insulin glulisine plays a vital role in acute blood glucose control, offering significant advantages over conventional insulins. Its market trajectory, driven by evolving healthcare dynamics, regulatory pathways, and technological innovations, underscores its position within the burgeoning biologics sector.

This analysis explores the current market landscape, competitive forces, regulatory considerations, and financial prospects shaping insulin glulisine’s future.

Market Overview

Global Diabetes Epidemic and Growing Demand for Insulin Therapies

The proliferation of diabetes globally underpins the increased demand for insulin therapies, including rapid-acting analogs like insulin glulisine. The International Diabetes Federation reports that approximately 537 million adults were diabetic in 2021, with projections reaching 643 million by 2030.[1] The rising prevalence fuels the adoption of insulin analogs, with rapid-acting insulins accounting for a significant share due to their insulin kinetics suitable for mealtime glucose management.

Key Market Players and Competitive Landscape

Sanofi’s insulin glulisine faces competition from both originator products and biosimilars. Lilly’s rapid-acting insulin aspart and Novo Nordisk's insulin lispro are prominent competitors. The entry of biosimilars further intensifies competitive pressure, with companies seeking to capture market share through pricing strategies and innovative delivery formats.

Geographical Market Distribution

North America, especially the United States, dominates insulin sales owing to high diabetes prevalence, advanced healthcare infrastructure, and favorable reimbursement policies. Europe follows, with emerging markets like China and India increasingly contributing to volume growth driven by expanding healthcare access and awareness campaigns.

Market Dynamics

Regulatory Environment

Insulin glulisine has benefited from regulatory frameworks favoring biologics, including pathways for biosimilar approvals, which aim to foster competition and reduce costs.[2] The FDA's approval process emphasizes biosimilarity, clinical comparability, and safety, influencing market entry strategies for biosimilar versions.

Technological Innovations and Formulation Enhancements

Advancements in delivery devices—such as insulin pens and continuous subcutaneous infusion pumps—enhance patient adherence and convenience. The development of biosimilars often incorporates formulation improvements, aiming for better stability, ease of use, and reduced injection frequency.

Pricing and Reimbursement Dynamics

Price sensitivity among payers and increasing scrutiny over drug costs impact market penetration. Biosimilars facilitate price competition, potentially reducing costs by 15-30% relative to originator drugs.[3] Reimbursement policies favoring biosimilar adoption can accelerate market share expansion.

Patent Landscape and Market Entry Barriers

While Sanofi’s patent protection has historically limited biosimilar entry, patent expirations and legal challenges create windows for biosimilar manufacturers. Navigating regulatory approval and manufacturing standards poses significant barriers but also opportunities for new entrants aiming for market disruption.

Distribution Channels and Access

Distribution networks, especially in emerging economies, influence market access. Partnerships with healthcare providers, pharmacies, and payers are critical to broadening reach and optimizing supply chains.

Financial Trajectory

Revenue Trends and Market Growth Projections

The global insulin market is projected to CAGR at approximately 8.2% from 2022 to 2027.[4] Insulin glulisine’s specific segment is expected to grow in tandem, driven by increased prescription volumes, biosimilar competition, and technological adoption.

Sanofi’s revenue from basal and prandial insulins, including glulisine, remains substantial, but emerging biosimilars and generics are poised to erode margins over time. Competitive pricing pressures necessitate strategic investments in biosimilar development and commercialization.

Impact of Biosimilar Penetration

Biosimilar insulins are forecasted to capture up to 40% of the insulin market share in Europe and North America by 2025.[5] The resultant price competition may compress the revenue of originator brands, influencing profitability and R&D investment strategies.

R&D and Lifecycle Management

Investments in biosimilar development, novel delivery systems, and combination therapies aim to sustain growth. Lifecycle management strategies involve reformulation, fixed-dose combinations, and digital health integrations to extend product relevance.

Regulatory and Reimbursement Risks

Regulatory delays and reimbursement hurdles can temper financial forecasts. Policies favoring biosimilar substitution and formulary prioritization influence market share and revenue streams.

Market Entry Strategies for Biosimilar Insulin Glulisine

Successful biosimilar entrants engage in strategic partnerships, aggressive pricing, and educational campaigns. Ensuring manufacturing scalability and maintaining high standards for biosimilarity are critical to gaining acceptance in sensitive markets like the U.S. and European Union.

Future Outlook

The forecast indicates sustained growth for insulin glulisine, particularly in biosimilar forms. Key growth drivers include expanding global diabetes prevalence, technological innovations, aggressive biosimilar strategies, and evolving healthcare policies that favor cost-effective biologic therapies.

Conversely, market risks—such as patent litigations, regulatory delays, and payer resistance—may temper growth. Companies investing in R&D, digital health integration, and patient-centric formulations position themselves favorably for future expansion.

Conclusion

Insulin glulisine operates in a complex, dynamic landscape characterized by robust demand, technological innovations, and competitive pressures. The forthcoming years of its market trajectory will depend heavily on biosimilar development, regulatory navigation, and strategic pricing. As the global diabetes crisis intensifies, insulin glulisine has substantial growth potential, provided stakeholders adapt swiftly to evolving market forces.

---

Key Takeaways

• The global rise in diabetes cases drives sustained demand for rapid-acting insulins, including insulin glulisine.
• Market growth is accelerated by biosimilar competition, technological innovations, and evolving reimbursement policies.
• Regulatory frameworks and patent expirations are pivotal, offering both opportunities and challenges.
• Biosimilar insulins are poised to capture significant market share, compelling originator companies to innovate and strategize.
• Financial prospects hinge on successful biosimilar commercialization, cost management, and adaptation to healthcare policy changes.

---

FAQs

1. What factors influence the adoption of biosimilar insulin glulisine?
Regulatory approval, pricing strategies, payer acceptance, clinical efficacy perceptions, and healthcare provider familiarity drive biosimilar adoption.

2. How does insulin glulisine differ from other rapid-acting insulins?
Insulin glulisine has a unique amino acid sequence allowing for rapid onset and shorter duration compared to traditional insulins, providing flexible mealtime dosing.

3. What are the main challenges faced by biosimilar development?
Ensuring biosimilarity, manufacturing complexity, regulatory approval hurdles, and gaining clinician trust pose significant challenges.

4. How do reimbursement policies affect insulin market dynamics?
Policies favoring biosimilars promote cost savings but require establishing equivalence and provider education, influencing market penetration.

5. What role does technological innovation play in insulin therapy's future?
Advanced delivery devices, digital health integration, and personalized medicine approaches enhance adherence, efficacy, and market competitiveness.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 9th Edition, 2019.
[2] U.S. Food and Drug Administration. Biosimilar Approval Pathway, 2022.
[3] IQVIA. The Impact of Biosimilars on Insulin Pricing and Market Share, 2021.
[4] MarketsandMarkets. Insulin Market by Type, Region, and Application, 2022.
[5] Evaluate Pharma. Biosimilar Insulins Forecast, 2022.